Literature DB >> 19147567

Noncationic peptides obtained from azurin preferentially enter cancer cells.

Brad N Taylor1, Rajeshwari R Mehta, Tohru Yamada, Fatima Lekmine, Konstantin Christov, Ananda M Chakrabarty, Albert Green, Laura Bratescu, Anne Shilkaitis, Craig W Beattie, Tapas K Das Gupta.   

Abstract

Azurin, a member of the cupredoxin family of copper containing redox proteins, preferentially penetrates human cancer cells and exerts cytostatic and cytotoxic (apoptotic) effects with no apparent activity on normal cells. Amino acids 50 to 77 (p28) of azurin seem responsible for cellular penetration and at least part of the antiproliferative, proapoptotic activity of azurin against a number of solid tumor cell lines. We show by confocal microscopy and fluorescence-activated cell sorting that amino acids 50 to 67 (p18) are a minimal motif (protein transduction domain) responsible for the preferential entry of azurin into human cancer cells. A combination of inhibitors that interfere with discrete steps of the endocytotic process and antibodies for caveolae and Golgi-mediated transport revealed that these amphipathic, alpha-helical peptides are unique. Unlike the cationic cell-penetrating peptides, alpha-helical antennapedia-like, or VP22 type peptides, p18 and p28 are not bound by cell membrane glycosaminoglycans and preferentially penetrate cancer cells via endocytotic, caveosome-directed, and caveosome-independent pathways. Once internalized, p28, but not p18, inhibits cancer cell proliferation initially through a cytostatic mechanism. These observations suggest the azurin fragments, p18 and p28, account for the preferential entry of azurin into human cancer cells and a significant amount of the antiproliferative activity of azurin on human cancer cells, respectively.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19147567     DOI: 10.1158/0008-5472.CAN-08-2932

Source DB:  PubMed          Journal:  Cancer Res        ISSN: 0008-5472            Impact factor:   12.701


  42 in total

1.  Translocation of a thioether-bridged azurin peptide fragment via the sec pathway in Lactococcus lactis.

Authors:  Anneke Kuipers; Rick Rink; Gert N Moll
Journal:  Appl Environ Microbiol       Date:  2009-03-27       Impact factor: 4.792

Review 2.  Potent and tumor specific: arming bacteria with therapeutic proteins.

Authors:  Nele Van Dessel; Charles A Swofford; Neil S Forbes
Journal:  Ther Deliv       Date:  2015-03

Review 3.  Bacterial cupredoxin azurin hijacks cellular signaling networks: Protein-protein interactions and cancer therapy.

Authors:  Meng Gao; Jingjing Zhou; Zhengding Su; Yongqi Huang
Journal:  Protein Sci       Date:  2017-10-27       Impact factor: 6.725

Review 4.  Modifications of natural peptides for nanoparticle and drug design.

Authors:  Andrew P Jallouk; Rohun U Palekar; Hua Pan; Paul H Schlesinger; Samuel A Wickline
Journal:  Adv Protein Chem Struct Biol       Date:  2015-03-12       Impact factor: 3.507

5.  Bioengineered bugs, drugs and contentious issues in patenting.

Authors:  Ananda M Chakrabarty
Journal:  Bioeng Bugs       Date:  2010 Jan-Feb

Review 6.  Microbial-based therapy of cancer: current progress and future prospects.

Authors:  Nuno Bernardes; Raquel Seruca; Ananda M Chakrabarty; Arsenio M Fialho
Journal:  Bioeng Bugs       Date:  2009-12-02

7.  Modulation of membrane properties of lung cancer cells by azurin enhances the sensitivity to EGFR-targeted therapy and decreased β1 integrin-mediated adhesion.

Authors:  Nuno Bernardes; Sofia Abreu; Filomena A Carvalho; Fábio Fernandes; Nuno C Santos; Arsénio M Fialho
Journal:  Cell Cycle       Date:  2016-04-20       Impact factor: 4.534

8.  Escherichia coli Nissle 1917 targets and restrains mouse B16 melanoma and 4T1 breast tumors through expression of azurin protein.

Authors:  Yunlei Zhang; Youming Zhang; Liqiu Xia; Xiangli Zhang; Xuezhi Ding; Fu Yan; Feng Wu
Journal:  Appl Environ Microbiol       Date:  2012-08-24       Impact factor: 4.792

9.  Phase I trial of p28 (NSC745104), a non-HDM2-mediated peptide inhibitor of p53 ubiquitination in pediatric patients with recurrent or progressive central nervous system tumors: A Pediatric Brain Tumor Consortium Study.

Authors:  Rishi R Lulla; Stewart Goldman; Tohru Yamada; Craig W Beattie; Linda Bressler; Michael Pacini; Ian F Pollack; Paul Graham Fisher; Roger J Packer; Ira J Dunkel; Girish Dhall; Shengjie Wu; Arzu Onar; James M Boyett; Maryam Fouladi
Journal:  Neuro Oncol       Date:  2016-03-28       Impact factor: 12.300

Review 10.  Anticancer Actions of Azurin and Its Derived Peptide p28.

Authors:  Fan Huang; Qianhui Shu; Zhaojie Qin; Jianglin Tian; Zhengding Su; Yongqi Huang; Meng Gao
Journal:  Protein J       Date:  2020-04       Impact factor: 2.371

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.